CTLA4 and neoplasm: Interestingly, it has been suggested that a pre-existing immune-active tumor microenvironment is what mediates the anti-tumor activity of CTLA-4 blockade; hence, one may speculate that stromal CTLA-4 expression may have potential as a predictive marker for anti-CTLA-4 treatment in NSCLC patients [49].